Nextmune, the operating company within Vimian’s Specialty Pharma segment, has signed an agreement to acquire Laboratoire de Dermo-Cosmétique Animale (LDCA). LDCA is a French pet dermatology specialist company that provides innovative and evidence-based natural topical products for the wellbeing of animals through its Dermoscent brand.
LDCA, based in France, is a companion animal dermatology specialist company that provides prescribing veterinarians and pet owners with innovative and natural topical products through its Dermoscent brand to complement medicinal treatments and limit excessive use of medicines through a multimodal approach. The range of Dermoscent provides evidence-based, efficacious solutions to veterinarians and pet owners to enhance the skin health as well as physical and psychological wellbeing of animals. Every product formula is proprietary and developed by a team of veterinary dermatologists and pharmaceutical specialists. The brand Dermoscent is acknowledged by both veterinarians and pet owners. Founded in 2003 with products distributed in more than 45 countries, LDCA has revenues of approximately €5 million in the last 12 months.
“The acquisition of LDCA and its highly regarded Dermoscent products bolsters our offering of dermatology products and complements our expanding non-prescription portfolio. Also, LDCA will strengthen our market position in France across therapeutic areas and provide further capillarity through its international distributor network. We look forward to working together with the management team of LDCA to continue expanding the portfolio of leading topical treatments for pets”, says Magnus Kjellberg, CEO of Nextmune.
The acquisition will have a marginal impact on Vimian Group AB’s earnings per share in the current financial year and closing is subject to customary closing conditions.